ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
1-Year Est. Return
11.37%
1 Year Est. Return
+11.37%
AUM
$5.71B
AUM Growth
-$696M
(-11%)
Holding
34
Top Buys
| 1 | +$187M | |
| 2 | +$65.1M | |
| 3 | +$20.2M | |
| 4 |
Vera Therapeutics
VERA
|
+$14.1M |
| 5 |
Alkermes
ALKS
|
+$12.9M |
Top Sells
| 1 | +$445M | |
| 2 | +$171M | |
| 3 | +$87.6M | |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$82.5M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$44.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$12.5B
| $860M | 15.05% |
4,980,000
-238,000
|
|
||
2
United Therapeutics
UTHR
$19.5B
| $681M | 11.93% |
2,370,000
-305,000
|
|
||
3
argenx
ARGX
$50.2B
| $648M | 11.34% |
1,175,000
-60,177
|
|
||
|
4
Madrigal Pharmaceuticals
MDGL
$9.66B
| $567M | 9.94% |
1,875,000
-147,222
|
|
||
5
Krystal Biotech
KRYS
$5.59B
| $366M | 6.4% |
2,660,000
-71,000
|
|
||
6
Kymera Therapeutics
KYMR
$4.5B
| $286M | 5.01% |
6,555,555
+95,555
|
|
||
7
Apellis Pharmaceuticals
APLS
$3.19B
| $212M | 3.71% |
12,222,222
|
|
||
8
Avidity Biosciences
RNA
$7.36B
| $200M | 3.51% |
7,050,000
-575,000
|
|
||
9
MoonLake Immunotherapeutics
MLTX
$628M
| $196M | 3.43% |
4,150,000
+1,379,900
|
|
||
10
Akero Therapeutics
AKRO
$4.3B
| $187M | 3.27% |
+3,500,000
|
|
||
11
Soleno Therapeutics
SLNO
$3.6B
| $172M | 3.01% |
2,050,000
-475,000
|
|
||
12
Xenon Pharmaceuticals
XENE
$3.23B
| $169M | 2.96% |
5,400,000
-341,666
|
|
||
13
Arrowhead Research
ARWR
$5.28B
| $167M | 2.93% |
10,600,000
-511,111
|
|
||
14
Merus
MRUS
$7.2B
| $166M | 2.91% |
3,155,555
+155,555
|
|
||
|
15
Vera Therapeutics
VERA
$1.98B
| $148M | 2.6% |
6,300,000
+598,100
|
|
||
16
Amicus Therapeutics
FOLD
$2.58B
| $103M | 1.81% |
18,000,000
-2,500,000
|
|
||
|
17
Alkermes
ALKS
$5.32B
| $83M | 1.45% |
2,900,000
+450,000
|
|
||
18
Ocular Therapeutix
OCUL
$2.53B
| $68.7M | 1.2% |
7,400,000
-660,000
|
|
||
19
89bio
ETNB
$2.2B
| $66.3M | 1.16% |
6,750,000
+400,000
|
|
||
|
CNTA
20
Centessa Pharmaceuticals
CNTA
$3.03B
| $65.7M | 1.15% |
5,000,000
+950,000
|
|
||
21
uniQure
QURE
$3.87B
| $50.5M | 0.88% |
3,625,000
+1,450,000
|
|
||
22
Taysha Gene Therapies
TSHA
$1.46B
| $50.1M | 0.88% |
21,700,000
+1,700,001
|
|
||
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $48.1M | 0.84% |
375,000
-3,475,000
|
|
||
24
Tourmaline Bio
TRML
$1.23B
| $40.9M | 0.72% |
2,555,555
+130,555
|
|
||
25
BioCryst Pharmaceuticals
BCRX
$1.43B
| $40.3M | 0.71% |
4,500,000
-4,200,000
|
|